On December 16, 2025, a groundbreaking study revealed Fab5, an antibody capable of protecting mice, non-human primates, and humanized mice from multiple deadly gammaherpesviruses. This feat was previously considered impossible.
Antiviral and vaccine development for herpesviruses has long been hampered by strain specificity. Yet, Fab5 shatters this barrier, demonstrating broad protection by targeting a universally conserved viral vulnerability.
Fab5's unprecedented cross-genus efficacy and novel epitope targeting will likely reshape future antiviral strategies. We can expect a shift towards identifying and exploiting similar broadly conserved viral vulnerabilities, potentially paving the way for more universal treatments.
How Fab5 Achieves Broad Protection
Fab5, a monoclonal antibody isolated from EBV chimeric nanoparticle-immunized mice, exhibits broad and high affinity to gammaherpesvirus gB, as reported by Nature Communications. This strong binding allows Fab5 to effectively inhibit gB-dependent cell–cell fusion, neutralize authentic infection, and protect against multiple pathogenic human and animal gammaherpesviruses, according to a broadly protective antibody targeting gammaherpesvirus gb. Essentially, Fab5's potent activity stems from its ability to tightly bind and disable critical viral functions across a wide spectrum of these viruses. This suggests that targeting such fundamental viral machinery could offer a robust defense against even highly diverse pathogens.
Uncovering a Universal Vulnerability
Fab5 targets a previously unreported epitope on gammaherpesvirus gB. This epitope is remarkably conserved across the herpesvirus family and remains exposed in both pre-fusion and post-fusion states of gB, as detailed in Nature and confirmed by a broadly protective antibody targeting gammaherpesvirus gb. This consistent exposure, regardless of the virus's conformational changes, is key to Fab5's broad efficacy. The identification of such a universally exposed and vulnerable epitope on the gB protein opens a new avenue for developing broad-spectrum antiviral therapies, moving beyond the limitations of strain-specific approaches.
